Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9327002 | 0.89 | ADORA2A (0.71) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL9325869 | 0.85 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL9327300 | 0.84 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL9329035 | 0.84 | ADORA2A (0.77) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL9327307 | 0.83 | ADORA2A (0.72) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL7834626 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL21936929 | 0.83 | ADORA2A (0.74) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29853688 | 0.82 | ADORA2A (0.85) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL9327262 | 0.82 | ADORA2A (0.73) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL9327281 | 0.81 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2BHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ITEOS BELGIUM S A (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11427594-B2 | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers | iTeos Belgium SA (BE) | 2022-08-30 | — | — | US | disclosed |
| US-20200102319-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20200102319-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102319-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-11427594-B2 | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.